Advertisement

Topics

Bristol-Myers Squibb to Acquire IFM Therapeutics in $300M Upfront Deal

09:10 EDT 4 Aug 2017 | PharmPro

Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity. IFM Therapeutics to receive $300 million upfront with potential of up to $1.01 billion in milestones for each of the first products from two programs.
Contributed Author: 
Bristol-Myers Squibb Company
Topics: 

Original Article: Bristol-Myers Squibb to Acquire IFM Therapeutics in $300M Upfront Deal

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb to Acquire IFM Therapeutics in $300M Upfront Deal"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...